MUC1-Binding Polypeptide CARs for Sustained Cancer Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anticancer therapies using antibodies targeting mucin1 are limited by short duration of effect and resistance development, necessitating a technology that can continuously activate the immune system against various cancers.

Innovation Solution

Development of a polypeptide that binds to mucin1, encoded by a specific polynucleotide, and integrated into a chimeric antigen receptor (CAR) for immune cells to enhance cancer treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibodies are used for cancer treatment, then cancer cells can be targeted, but the duration of effect is short and resistance occurs

Engineering Contradiction:

Improveanticancer effect durationVSAvoidduration of effect

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent replaces passive antibody-based mechanical targeting with an active immune system activation approach. The polypeptide binds to MUC1 on cancer cells and triggers immune cell recruitment and activation, transforming the treatment mechanism from direct antibody-cancer interaction to immune-mediated destruction, thereby extending the duration of anticancer effect and reducing resistance development.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces an intermediary mechanism where the polypeptide acts as a bridge between cancer cells and the immune system. By binding to MUC1 and facilitating immune cell recruitment, the polypeptide serves as a mediator that sustains immune activation over time, overcoming the limited duration of direct antibody therapy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If antibodies are used for cancer treatment, then cancer cells can be targeted, but resistance occurs during prolonged use

Engineering Contradiction:

Improveanticancer effect sustainabilityVSAvoidresistance

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent substitutes the passive antibody targeting mechanism with an active immune activation system. The polypeptide-MUC1 interaction triggers multiple immune cell types to attack cancer cells, creating a more robust and sustainable anticancer effect that is less prone to resistance development compared to direct antibody therapy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent enables the immune system to self-activate and self-sustain the anticancer response. The polypeptide serves as a trigger that initiates immune cell recruitment and activation, allowing the immune system to maintain its own anticancer activity without continuous external intervention, thereby reducing resistance to prolonged treatment.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS20250281533A1Polypeptide specific for mucin 1 and use thereof

Publication Date: 2025.09.11 LG CHEM LTD

AI summary

The present invention relates to a polypeptide binding to mucin 1, an isolated polynucleotide encoding same, a vector carrying the polynucleotide, and a cell including the vector. In addition, the present invention relates to a chimeric antigen receptor including the polypeptide binding to mucin 1, an isolated polynucleotide encoding the chimeric antigen receptor, a vector carrying the polynucleotide, an immune cell expressing the chimeric antigen receptor, a composition comprising same for treatment of cancer, and a method for treatment of cancer.